This is a paid press release. Contact the press release distributor directly with any inquiries.

Considering MEDVi Tirzepatide GLP-1 Weight Loss in 2026? Read This Before Enrolling in Any Tirzepatide GLP-1 Telehealth Weight Loss Program

MEDVI

Thu, February 26, 2026 at 10:16 AM GMT+9 15 min read

MEDVI

An independent informational overview of MEDVi’s compounded tirzepatide telehealth program, including regulatory classification, platform structure, pricing disclosures, and key consumer verification steps.

NEWARK, DE, Feb. 25, 2026 (GLOBE NEWSWIRE) – Disclaimer: This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Compounded medications are not FDA-approved finished products. Consult a licensed healthcare provider before starting any weight loss program or medication. If you purchase through links in this article, a commission may be earned at no additional cost to you.

If you have been researching tirzepatide-based weight loss programs, you are not alone. The telehealth-assisted weight management space has grown considerably over the past several years, fueled by rising interest in GLP-1 receptor agonist medications and the expanding availability of remote prescribing platforms. Within that broader landscape, compounded GLP-1 programs have carved out a notable segment, offering an alternative pathway to brand-name medications through pharmacies that operate under applicable federal and state compounding regulations.

This article provides an informational overview of MEDVi’s tirzepatide-based GLP-1 telehealth program, including publicly available disclosures, regulatory context, and structural considerations. It is not a recommendation or endorsement. Readers are encouraged to review official materials and consult with a licensed healthcare provider before making decisions regarding prescription medications.

Considering MEDVi Tirzepatide GLP-1 Weight Loss in 2026 Read This Before Enrolling in Any Tirzepatide GLP-1 Telehealth Weight Loss Program

This informational overview was prepared by an independent digital publisher. The publisher may maintain a commercial relationship with the brand referenced.

View the current MEDVi Tirzepatide offer (official MEDVi page)

What MEDVi Tirzepatide GLP-1 Weight Loss Is (Classification First)

At its core, MEDVi is a telehealth patient management platform — not a doctor’s office and not a pharmacy. It facilitates access to compounded GLP-1 receptor agonist medications, including tirzepatide formulations, for weight management purposes. According to the company’s publicly available disclosures, MEDVi, LLC is a Delaware corporation headquartered at 131 Continental Dr, Ste 305, Newark, DE 19713.

Understanding who does what in this model matters, because three separate entities are involved. MEDVi itself operates as the technology and administrative platform — think of it as the front door. Healthcare services, including medical evaluations and the actual prescribing decisions, are provided by independent licensed clinicians through affiliated professional entities. At the time of this writing, the company identifies these affiliates on its website as OpenLoop Health and CareGLP Affiliated P.C.s. Prescription fulfillment is then handled by separate partnered pharmacies that the company describes as USA-certified facilities.

繼續閱讀  

Why does this separation matter to you? Because MEDVi does not directly provide medical or pharmacy services. The company explicitly states that payment does not guarantee the writing or dispensing of a prescription. The clinician who reviews your case makes that call independently, based on their own medical judgment.

Regulatory Framework for Compounded Tirzepatide

The regulatory classification of the medications in this program is an important consideration for prospective participants.

According to the company’s disclosures, the compounded GLP-1 medications available through MEDVi are produced in facilities that operate under applicable federal and state compounding regulations. However, the company clearly states that while these facilities are subject to regulatory oversight, the compounded medications themselves are not FDA-approved and have not been evaluated by the FDA for safety, efficacy, or quality as finished products.

Here is why that distinction is significant. FDA-approved tirzepatide products — the branded medications manufactured by their original pharmaceutical developer — go through extensive clinical trial processes and ongoing post-market surveillance. Compounded versions, while produced under regulatory oversight, follow a different pathway entirely. The decision to prescribe a compounded medication rests with the licensed provider’s independent medical judgment, informed by a telehealth consultation and a review of your medical history.

The company encourages prospective users to discuss the specific risks and benefits of compounded medications with their provider. MEDVi also discloses that it does not produce compounded medications directly, and that the medication you receive may look different from what is shown on the company’s website.

How the MEDVi Telehealth Model Works

If you are wondering what the actual process looks like from start to finish, here is how the MEDVi platform is structured based on publicly available information from their website.

It starts with an online health assessment that you complete through the MEDVi site. This is essentially a screening questionnaire, and completing it does not create a doctor-patient relationship between the individual and MEDVi. The company’s affiliated medical network has established exclusionary criteria that determine whether you move forward or are screened out of eligibility based on your responses.

If you pass the initial screening, a licensed clinician from the affiliated provider network conducts a consultation with you after checkout to make an independent determination about whether a prescription is appropriate for your situation. The company states that these clinicians retain sole decision-making authority over whether to prescribe compounded GLP-1 medications. In other words, a real licensed provider reviews your case — and they can say no.

If a prescription is issued, the medication is dispensed by a partnered pharmacy and shipped directly to your door. All prescription medications are dispensed according to state and federal law with the approval of the pharmacist in charge.

What the MEDVi Tirzepatide Program Includes

Beyond the medication itself, the MEDVi program bundles several components into its pricing. According to the company’s publicly listed program details, enrollment covers a physician review, a personalized care plan, one-on-one guidance, a metabolic report, and the cost of the prescription medication with shipping included.

The platform lists both injectable and oral GLP-1 formulations. Injectable options are described as once-weekly injections, while oral options are described as daily dissolvable tablets. Consumers considering enrollment may confirm the exact formulation details — including the specific active ingredients and concentrations — with the prescribing clinician and the dispensing pharmacy directly.

The company also describes unlimited 24/7 support as part of the program, including access to specialists, unlimited appointments, messaging, and ongoing clinical support. These are the company’s stated service commitments, and as with any service offering, your individual experience may vary depending on program participation and clinician availability.

Delivery, Usage, and Outcome Expectations

Once prescribed, your medication is shipped directly to the address you provide from the partnered pharmacy. The company states that shipping is free and expedited. Per the company’s shipping terms, medication is considered dispensed when it is signed out for shipping — not when it arrives at your door.

When it comes to what you might expect, the company’s disclosures indicate that patients on the program typically experience weight loss in the range of 1 to 2 pounds per week after the first four weeks, when combined with a healthy diet and exercise modifications. These figures come with important context — they are based on self-reported data from patients who also made dietary changes and increased their physical activity.

Here is the bottom line on outcomes: Results from compounded medications may vary and are influenced by your adherence to the program, your clinician’s recommendations, your starting weight, and your individual physiology. The company’s own disclosures are clear that their reported outcomes come from self-reported patient data collected through intake questionnaires every three to four weeks — not from independent clinical trials of the compounded formulations. No specific weight loss result is guaranteed.

Pricing Disclosures

Understanding exactly what you are paying — and what you are agreeing to — is essential before enrolling. Here is what the company publicly lists at the time of this article’s preparation.

The MEDVi program for compounded GLP-1 injections starts at $179 for the first month. Refills are listed at $299 per month. Oral GLP-1 tablet options start at $249 per month. The company also lists branded Ozempic injection access starting at $1,999 per month, with a note that quantities are limited and availability is subject to change.

According to the company, the listed pricing includes medication, physician review, care plan, and shipping. The company also states that HSA and FSA payment methods are accepted. That said, pricing is subject to change at the company’s discretion, and the final charge may fluctuate depending on the prescribed medication and the pharmacy selected for fulfillment.

Two additional disclosures are relevant. First, the company discloses that all programs are auto-renewing, meaning consumers will be automatically charged for ongoing enrollment unless they explicitly request cancellation before payment processes. Second, all affiliated medical providers operate on an out-of-network basis — they are not contracted with any health insurance plans, including Medicare, Medicaid, or commercial insurance. You are solely responsible for all fees.

Safety, Risks, and Limitations

Every medical decision carries potential risks, and a compounded GLP-1 telehealth program is no exception. Here are the key safety considerations you should evaluate before enrolling.

As covered in the regulatory section above, compounded GLP-1 medications are not FDA-approved finished products. They have not been independently evaluated for safety, efficacy, or quality by the FDA as finished drugs. The prescribing decision is based entirely on the individual clinician’s medical judgment.

The company’s telehealth consent disclosures also identify risks specific to the remote care model itself. These include rare instances where transmitted information may not be sufficient for appropriate medical decision-making, potential delays due to equipment or technology deficiencies, rare security protocol failures that could affect your medical information privacy, and the possibility that incomplete access to your full medical records could result in adverse drug interactions or allergic reactions.

The company’s weight loss consumer bill of rights disclosures include a warning about rapid weight loss, defining it as weight loss exceeding 1.5 to 2 pounds per week, or more than 1 percent of body weight per week after the second week of participation. Consumers are advised to consult a qualified healthcare provider before starting any weight loss program.

GLP-1 receptor agonist medications, including tirzepatide formulations, also carry known class-level side effects that you should discuss thoroughly with your prescribing clinician. Medication prescriptions are always at the discretion of the medical provider and may not be suitable for everyone.

What Consumers Commonly Verify Before Enrolling

Consumers conducting due diligence often review the following:

Business registration verification is a straightforward starting point. MEDVi, LLC is identified as a Delaware corporation with a registered address at 131 Continental Dr, Ste 305, Newark, DE 19713. You can verify this registration through the Delaware Division of Corporations public records.

Medical provider licensing is another critical area. The company identifies its affiliated medical provider networks on its website. You can verify the licensing status of individual prescribing clinicians through their respective state medical boards, which maintain publicly searchable databases.

Independent reviews across multiple platforms provide additional data points. Rather than relying on any single source, consumers can evaluate the company’s standing across several independent review platforms and pay attention to both recency and patterns in the feedback.

Terms and refund policy deserve a careful read before you enter payment information. At the time of this writing, the company’s refund policy states that consumers may be eligible for a refund — minus the stated consultation fee outlined in the company’s published refund policy — if they can demonstrate they have not lost weight after following the program for a minimum of five months. Medical consultation fees are separately stated as non-refundable. You should also be aware of the mandatory arbitration provision and class action waiver included in the company’s terms and conditions.

Finally, evaluate the thoroughness of the screening and intake process itself. The quality of any telehealth-based medical evaluation depends on how comprehensively your medical history is reviewed and how substantive the clinical assessment actually is.

How Compounded GLP-1 Telehealth Programs Compare to Other Models

If you are weighing your options, it helps to understand how this type of program fits within the broader landscape of GLP-1 weight management models available today.

Telehealth platforms versus in-person clinical settings represent the primary structural difference. Telehealth models offer accessibility and convenience, particularly if you live in an area with limited specialist availability. In-person settings may provide more comprehensive physical examinations and hands-on diagnostic capabilities. Both models require licensed prescribers to make independent clinical judgments about your care.

Compounded formulations versus FDA-approved branded products represent a meaningful regulatory distinction. FDA-approved tirzepatide and semaglutide products have been through extensive clinical trial processes with published safety and efficacy data. Compounded formulations are produced under regulatory oversight but are not individually evaluated by the FDA as finished products. The cost difference between these two pathways is often substantial, and that price gap is frequently a driving factor in consumer decision-making.

MEDVi also operates programs across multiple telehealth categories beyond weight management. For example, the company offers compounded telehealth programs in other health areas, including men’s health. If you are evaluating MEDVi as a platform overall, you may want to review how the company structures its programs across different categories. An independent informational overview of MEDVi’s compounded ED telehealth program provides additional context on the company’s broader telehealth model and regulatory positioning.

Subscription-based telehealth models versus traditional prescription pathways differ in how costs are structured. Subscription models like MEDVi’s typically bundle platform fees, consultation costs, and medication into a single recurring payment. Traditional pathways may involve separate charges for office visits, prescriptions, and pharmacy costs, with the potential for insurance coverage when FDA-approved medications are prescribed.

Evidence Boundaries

This section matters more than most people realize, and understanding it will help you evaluate any compounded GLP-1 program with clearer eyes — not just this one.

Tirzepatide as an active pharmaceutical ingredient has been studied extensively in published clinical trials. That research has demonstrated efficacy for weight management and glycemic control in specific study populations under controlled conditions. However, those studies were conducted using FDA-approved manufactured formulations with standardized dosing, quality controls, and regulatory oversight of the finished product.

Compounded formulations containing tirzepatide have not been independently studied in the same way. While the active ingredient is the same, compounded preparations may differ in formulation, concentration, bioavailability, stability, and other pharmacological characteristics from the branded versions used in clinical trials. The clinical evidence supporting tirzepatide’s efficacy applies specifically to the manufactured versions that were studied — not to compounded preparations.

The company’s own disclosures reinforce this boundary clearly, stating that no data, photos, claims, or other information on its website are associated with results from clinical trials, studies, or public research. All represented outcomes are described as coming from MEDVi patient experience based on self-reported data.

Summary of Key Considerations

The following summarizes key structural and regulatory considerations. MEDVi operates as a telehealth patient management platform that connects you with affiliated independent medical providers who may prescribe compounded GLP-1 medications, including tirzepatide formulations, if they determine it is clinically appropriate for your situation. The platform, the clinicians, and the pharmacy are separate entities with distinct roles and responsibilities.

The compounded medications available through the program are produced in facilities operating under applicable federal and state compounding regulations, but they are not FDA-approved finished products. That distinction carries meaningful implications for how consumers evaluate the safety, efficacy, and quality assurances associated with the medication received. This classification should be weighed against individual health circumstances, goals, and risk tolerance.

Pricing starts at $179 for the first month with refills at $299, with all services operating on a cash-pay, out-of-network basis. The program auto-renews, and the refund policy includes specific conditions and timeframes that you should review carefully before enrollment. Individual results vary based on program adherence, clinician recommendations, and your body’s individual response.

Readers seeking additional information may review the company’s official website, examine full terms and conditions, and consult with their healthcare provider before making decisions regarding prescription weight loss treatment.

View the current MEDVi Tirzepatide offer (official MEDVi page)

Contact Information

MEDVi, LLC

131 Continental Dr, Ste 305, Newark, DE 19713

Email: help@medvi.org

Phone: (323) 690-1564

Website: medvi.org

This informational overview was prepared by an independent digital publisher. The publisher may maintain a commercial relationship with the brand referenced.

Disclaimers

General Disclaimer: This article is for informational purposes only and does not constitute medical, financial, or professional advice. If you purchase through links in this article, a commission may be earned at no additional cost to you. The publisher maintains a separate commercial relationship with the brand.

Compounded Medication Notice: The compounded GLP-1 medications referenced in this article are produced in facilities that operate under applicable federal and state compounding regulations. Although these facilities are subject to regulatory oversight, the compounded medications themselves are not FDA-approved finished products and have not been evaluated by the FDA for safety, efficacy, or quality. The decision to prescribe compounded medications is made by licensed medical providers based on their independent clinical judgment.

Results Disclaimer: Individual results may vary significantly based on starting weight, program adherence, dietary and exercise modifications, medical history, and individual physiological response. Weight loss outcomes referenced in this article are based on company-reported data from self-reported patient experiences and are not derived from independent clinical trials of the compounded formulations. Medication prescriptions are at the sole discretion of licensed medical providers and may not be suitable for everyone.

Medical Advice Disclaimer: This article is not intended to diagnose, treat, cure, or prevent any disease or medical condition. Consumers are encouraged to consult with a qualified healthcare provider before starting any weight loss program, medication, or treatment. If you are experiencing a medical emergency, call 911 or your local emergency services immediately.

CONTACT: Email: help@medvi.org Phone: (323) 690-1564

條款 及 私隱政策

Privacy Dashboard

More Info